No Conflict of interest was declared.
Sibutramine usage in New Zealand: an analysis of prescription data by the Intensive Medicines Monitoring Programme†
Article first published online: 30 JUL 2007
Copyright © 2007 John Wiley & Sons, Ltd.
Pharmacoepidemiology and Drug Safety
Volume 16, Issue 11, pages 1217–1226, November 2007
How to Cite
Hill, G. R., Ashton, J. and Harrison-Woolrych, M. (2007), Sibutramine usage in New Zealand: an analysis of prescription data by the Intensive Medicines Monitoring Programme. Pharmacoepidem. Drug Safe., 16: 1217–1226. doi: 10.1002/pds.1447
- Issue published online: 26 OCT 2007
- Article first published online: 30 JUL 2007
- Manuscript Accepted: 4 JUN 2007
- Manuscript Revised: 31 MAY 2007
- Manuscript Received: 25 FEB 2007
- prescribing patterns;
- body mass index (BMI);
- Intensive Medicines Monitoring Programme (IMMP)
To describe patterns of sibutramine usage in New Zealand during the first 3 years of marketing using data acquired during post-marketing safety surveillance.
Demographic and prescription data were examined from a nationwide cohort of 17 298 patients prescribed sibutramine between 1 February 2001 and 31 March 2004. Outcome measures were age and sex distribution of the cohort; period prevalence of sibutramine usage for each ethnic group; duration of treatment and reasons for cessation of therapy. Limited BMI data were also examined.
About 0.5% of the NZ population were prescribed sibutramine in the period studied. Overwhelmingly, the highest users of sibutramine were NZ European women aged 30–59 years. Maori and Pacific Peoples were under-represented in the cohort, despite the higher prevalence of obesity among these populations. Sibutramine usage was predominantly short-term: 59% of the cohort used sibutramine for 90 days or less, half of whom used it for only 1 month.
There has been extensive use of sibutramine in New Zealand. Sibutramine has been relatively under-utilised by Maori and Pacific ethnic groups, compared to New Zealand Europeans, despite their higher prevalence of obesity. A number of factors may have contributed to the predominantly short-term use of this medicine, including the cost of the medicine to the consumer, weight loss not meeting expectations and adverse effects of the medicine. Copyright © 2007 John Wiley & Sons, Ltd.